see Table 1) (EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2015)
The chart below shows three common reconstitution options with the resulting concentration and unit breakdowns for standard doses
Short-Term Response Some patients report noticing initial changes in comfort and function within weeks of beginning treatment, though individual experiences vary
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: A phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
If you are unsure about preparation, dosing, or storage, ask a qualified clinician or pharmacist